Healthcare utilization and cost of pneumococcal disease in the United States

Vaccine

Volumn 29, Issue 18, 2011, Pages 3398-3412

  Huang, Susan S ^a,b   Johnson, Kristen M ^b   Ray, G Thomas ^c   Wroe, Peter ^b   Lieu, Tracy A ^b,d   Moore, Matthew R ^e   Zell, Elizabeth R ^e   Linder, Jeffrey A ^f   Grijalva, Carlos G ^g   Metlay, Joshua P ^h   Finkelstein, Jonathan A ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DIVISION OF RESEARCH   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Disease burden; Economic analysis; Pneumococcus; Streptococcus pneumoniae

Indexed keywords

CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; DEATH; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SURVEY; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OTITIS MEDIA; OUTPATIENT DEPARTMENT; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PRODUCTIVITY; SCHOOL CHILD; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINATION; WORK CAPACITY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DELIVERY OF HEALTH CARE; HEALTH CARE COSTS; HUMANS; INFANT; INPATIENTS; MIDDLE AGED; MODELS, ECONOMIC; OTITIS MEDIA; OUTPATIENTS; PNEUMOCOCCAL INFECTIONS; SEPSIS; SINUSITIS; UNITED STATES; YOUNG ADULT;

EID: 79954645991     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.088     Document Type: Article

References (30)

1. Butler J.C., Breiman R.F., Campbell J.F., Lipman H.B., Broome C.V., Facklam R.R. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. J Am Med Assoc 1993, 270:1826-1831.
2. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325(21):1453-1460.
3. Centers for Disease Control and Prevention (CDC) Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine - United States, 1997-2006. MMWR Morb Mortal Wkly Rep 2009, 58(01):1-4.
4. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J Am Med Assoc 2005, 294:2043-2051.
5. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746.
6. Smith P.J., Nuorti J.P., Singleton J.A., Zhao Z., Wolter K.M. Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey. Pediatrics 2007, 120:1165-1173.
7. US Department of Health and Human Services, National Center for Health Statistics. The National Immunization Survey, 2001-2006. Available from: [accessed 20.08.10]. http://www.cdc.gov/nis/.
8. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196:1346-1354.
9. Poehling K.A., Talbot T.R., Griffin M.R., Craig A.S., Whitney C.G., Zell E., et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. J Am Med Assoc 2006, 295(14):1668-1674.
10. Moore M.R., Gertz R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008, 197(7):1016-1027.
11. Centers for Disease Control and Prevention (CDC) Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae - Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep 2007, 56(41):1077-1080.
12. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(9568):1179-1186.
13. Grijalva C.G., Poehling K.A., Nuorti J.P., Zhu Y., Martin S.W., Edwards K.M., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006, 118(3):865-873.
14. Huang S.S., Hinrichsen V.L., Stevenson A.E., Rifas-Shiman S.L., Kleinman K., Pelton S.I., et al. Continued impact of pneumococcal conjugate vaccine on serotypes, antibiotic resistance, and risk factors for carriage in young children. Pediatrics 2009, 124(1):e1-e11.
15. Centers for Disease Control and Prevention (CDC) Influenza and pneumococcal vaccination coverage among persons aged 65 years and persons aged 18-64 years with diabetes or asthma-United States, 2003. MMWR Morb Mortal Wkly Rep 2004, 53:1007-1012.
16. Greene C.M., Kyaw M.H., Ray S.M., Schaffner W., Lynfield R., Barrett N.L., et al. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003. Clin Infect Dis 2006, 43(2):141-150. [Epub June 9, 2006].
17. Morrow A., De Wals P., Petit G., Guay M., Erickson L.J. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med 2007, 18(2):121-127.
18. O'Brien K.L., Wolfson L.J., Watt J.P., et al. Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
19. Cox E.D., Saluja S. Criteria-based diagnosis and antibiotic overuse for upper respiratory infections. Ambul Pediatr 2008, 8(4):250-254.
20. Lindbaek M., Melby K.K., Schoyen R., Hjortdahl P. Bacteriological findings in nasopharynx specimens from patients with a clinical diagnosis of acute sinusitis. Scand J Prim Health Care 2001, 19(2):126-130.
21. Gonzales R., Bartlett J.G., Besser R.E., Cooper R.J., Hickner J.M., Hoffman J.R., et al. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med 2001, 134(6):479-486.
22. American Academy of Pediatrics, Subcommittee on Management of Acute Otitis Media Diagnosis and management of acute otitis media. Pediatrics 2004, 113:1451-1465.
23. Grosse S.D., Krueger K.V., Mvundura M. Med Care 2009, 47(7(Suppl 1)):S94-103.
24. Capra A.M., Lieu T.A., Black S.B., Shinefield H.R., Martin K.E., Klein J.O. Pediatr Infect Dis J 2000, 19(4):354-355.
25. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201(1):32-41.
26. Kyaw M.H., Greene C.M., Schaffner W., Ray S.M., Shapiro M., Barrett N.L., et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Adults with invasive pneumococcal disease: missed opportunities for vaccination. Am J Prev Med 2006, 31(4):286-292. [Epub August 22, 2006].
27. Ridda I., Macintyre C.R., Lindley R., Gao Z., Sullivan J.S., Yuan F.F., et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009, 27(10):1628-1636.
28. Dransfield M.T., Nahm M.H., Han M.K., Harnden S., Criner G.J., Martinez F.J., et al. COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180(6):499-505.
29. Goldblatt D., Southern J., Andrews N., Ashton L., Burbidge P., Woodgate S., et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009, 49(9):1318-1325.
30. O'Brien K.L. Pneumococcal conjugate vaccine, polysaccharide vaccine, or both for adults? We're not there yet. Clin Infect Dis 2009, 49(9):1326-1328.